Pfizer Crushes Q1, Eyes Long-Term Growth episode artwork

EPISODE · May 5, 2026 · 1 MIN

Pfizer Crushes Q1, Eyes Long-Term Growth

from The Daily News Now! Business

Pfizers Q1 earnings surpass expectations, with adjusted EPS at $0.75 and revenue at $14.45B. Newer launches and acquisitions drive growth, offsetting Covid product decline. Pfizer invests heavily in pipeline, eyeing long-term gains like the $10B Metsera acquisition. Key trial data drops, including lung cancer drug results, position Pfizer for post-pandemic success. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/1b2d16db99f32b04

NOW PLAYING

Pfizer Crushes Q1, Eyes Long-Term Growth

0:00 1:17

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of The Daily News Now! Business?

This episode is 1 minute long.

When was this The Daily News Now! Business episode published?

This episode was published on May 5, 2026.

What is this episode about?

Pfizers Q1 earnings surpass expectations, with adjusted EPS at $0.75 and revenue at $14.45B. Newer launches and acquisitions drive growth, offsetting Covid product decline. Pfizer invests heavily in pipeline, eyeing long-term gains like the...

Can I download this The Daily News Now! Business episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!